Client Reference No.: 004012 US

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Co et al.

Application No.: 10/084,825

Filed: February 25, 2002

For: INCREASING ANTIBODY AFFINITY BY ALTERING GLYCOSYLATION OF IMMUNOGLOBULIN VARIABLE Examiner: Larry Helms

Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Co et al.

Application No.: 10/084,825

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joe Liebeschuetz Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor

San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

JOL:crf 60261100 v1

PTO/SB/08A (08-03) stitute for form 1449A/PTO Complete if Known 10/084,825 **Application Number** INFORMATION DISCLOSURE February 25, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Co, Man Sung 1642 Art Unit (use as many sheets as necessary) **Examiner Name** Larry Helms 011823-004012US Sheet Attorney Docket Number

U.S. PATENT DOCUMENTS+						
	Document Number					
Cite No.1	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
AA	US-6,218,149	04-17-2001	Morrison et al.	***		
*						
		Cite No.1 Number Kind Code <sup>2</sup> (if known)  AA US-6,218,149	Document Number	Cite No.1 Number Kind Code <sup>2</sup> (if known) Publication Date MM-DD-YYYY Applicant of Cited Document  AA US-6,218,149 04-17-2001 Morrison et al.		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup>	Foreign Patent Doc Number <sup>4</sup>	ument Kind Code <sup>s</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	AB	WO	03/016466	A2	02-27-2003			
				,				
***								
		1						

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to place a check mark here if English language Translation is attached. 

60261100 v1

substitute for form 1449B/PTO Complete if Known 10/084,825 Application Number INFORMATION DISCLOSURE February 25, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Co, Man Sung Art Unit 1642 (use as many sheets as necessary) Examiner Name Larry Helms 011823-004012US Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	CO et al., "Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody," Mol. Immunol., 30:1361 (1993).	
	AD	COLMA et al., "Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti- (1-6) dextran antibody," <u>Jour. Immunol.</u> , 162:2162 (1999).	
	AE	GALA et al., "V region carbohydrate and antibody expression," <u>Jour. Immunol.</u> , 172:5494 (2004).	
			i
		·	
<u> </u>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.